{"id":63459,"date":"2026-04-17T21:55:38","date_gmt":"2026-04-17T13:55:38","guid":{"rendered":"https:\/\/flcube.com\/?p=63459"},"modified":"2026-04-17T21:55:39","modified_gmt":"2026-04-17T13:55:39","slug":"mabwell-bioscience-expands-southeast-asia-reach-with-malaysian-licensing-deal-for-denosumab-biosimilars-rexeva-and-denosu","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63459","title":{"rendered":"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu"},"content":{"rendered":"\n<p><strong>Mabwell (Shanghai) Bioscience Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688062:SHA\">SHA: 688062<\/a>) has announced a new <strong>licensing agreement<\/strong> with a strategic partner in <strong>Malaysia<\/strong> for its two <strong>denosumab biosimilars<\/strong>, <strong>Rexeva<\/strong> and <strong>Denosu<\/strong>. The deal marks a key step in Mabwell\u2019s international commercialization strategy for its oncology and bone health portfolio.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-product-portfolio\">Deal Structure &amp; Product Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licenser<\/strong><\/td><td>Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Undisclosed strategic partner in Malaysia<\/td><\/tr><tr><td><strong>Products<\/strong><\/td><td><strong>Rexeva<\/strong> (Prolia biosimilar) &amp; <strong>Denosu<\/strong> (Xgeva biosimilar)<\/td><\/tr><tr><td><strong>Mabwell Responsibilities<\/strong><\/td><td>Product development, manufacturing, and commercial supply<\/td><\/tr><tr><td><strong>Partner Responsibilities<\/strong><\/td><td>Local registration and sales in Malaysia<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-profiles-amp-chinese-approvals\">Asset Profiles &amp; Chinese Approvals<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Denosu (Xgeva biosimilar):<\/strong><\/li>\n\n\n\n<li><strong>Approved in China:<\/strong> March 2024.<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Treatment of <strong>unresectable giant cell tumor of bone<\/strong> or cases where surgery may cause severe functional impairment in adults and skeletally mature adolescents.<\/li>\n\n\n\n<li><strong>Significance:<\/strong> The <strong>first Xgeva knock-off<\/strong> approved in China.<\/li>\n\n\n\n<li><strong>Rexeva (Prolia biosimilar):<\/strong><\/li>\n\n\n\n<li><strong>Approved in China:<\/strong> April 2023.<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Treatment of <strong>osteoporosis in postmenopausal women at risk of fracture<\/strong>.<\/li>\n\n\n\n<li><strong>Significance:<\/strong> The <strong>second Prolia copycat<\/strong> to gain global approval.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p>This partnership leverages Mabwell\u2019s robust biosimilar development and manufacturing capabilities with its partner\u2019s established regulatory and commercial infrastructure in the Malaysian market. It provides Mabwell with a capital-efficient pathway to expand its geographic footprint in Southeast Asia without building a dedicated local sales force.<\/p>\n\n\n\n<p>The move also validates the quality and regulatory standing of Mabwell\u2019s biosimilar platform, as both products have already secured approval from China\u2019s stringent NMPA. Access to the Malaysian market represents an important foothold for further expansion across the ASEAN region.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the regulatory and commercial success of Rexeva and Denosu in Malaysia. Actual results are subject to local regulatory approvals, market access, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[118,1129],"class_list":["post-63459","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-mabwell-bioscience","tag-sha-688062"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a strategic partner in Malaysia for its two denosumab biosimilars, Rexeva and Denosu. The deal marks a key step in Mabwell\u2019s international commercialization strategy for its oncology and bone health portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63459\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu\" \/>\n<meta property=\"og:description\" content=\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a strategic partner in Malaysia for its two denosumab biosimilars, Rexeva and Denosu. The deal marks a key step in Mabwell\u2019s international commercialization strategy for its oncology and bone health portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63459\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-17T13:55:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-17T13:55:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63459#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63459\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu\",\"datePublished\":\"2026-04-17T13:55:38+00:00\",\"dateModified\":\"2026-04-17T13:55:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63459\"},\"wordCount\":302,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Mabwell Bioscience\",\"SHA: 688062\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63459#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63459\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63459\",\"name\":\"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-17T13:55:38+00:00\",\"dateModified\":\"2026-04-17T13:55:39+00:00\",\"description\":\"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a strategic partner in Malaysia for its two denosumab biosimilars, Rexeva and Denosu. The deal marks a key step in Mabwell\u2019s international commercialization strategy for its oncology and bone health portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63459#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63459\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63459#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu - Insight, China&#039;s Pharmaceutical Industry","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a strategic partner in Malaysia for its two denosumab biosimilars, Rexeva and Denosu. The deal marks a key step in Mabwell\u2019s international commercialization strategy for its oncology and bone health portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63459","og_locale":"en_US","og_type":"article","og_title":"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu","og_description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a strategic partner in Malaysia for its two denosumab biosimilars, Rexeva and Denosu. The deal marks a key step in Mabwell\u2019s international commercialization strategy for its oncology and bone health portfolio.","og_url":"https:\/\/flcube.com\/?p=63459","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-17T13:55:38+00:00","article_modified_time":"2026-04-17T13:55:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63459#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63459"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu","datePublished":"2026-04-17T13:55:38+00:00","dateModified":"2026-04-17T13:55:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63459"},"wordCount":302,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Mabwell Bioscience","SHA: 688062"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63459#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63459","url":"https:\/\/flcube.com\/?p=63459","name":"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-17T13:55:38+00:00","dateModified":"2026-04-17T13:55:39+00:00","description":"Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a strategic partner in Malaysia for its two denosumab biosimilars, Rexeva and Denosu. The deal marks a key step in Mabwell\u2019s international commercialization strategy for its oncology and bone health portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63459#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63459"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63459#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63459"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63459\/revisions"}],"predecessor-version":[{"id":63461,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63459\/revisions\/63461"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}